Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
preprocessed thawed autologous FMT
- Development stage
- Unknown
- Lead developer
- Universitetssykehuset Nord-Norge
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Preprocessed thawed autologous fecal microbiota transplant (FMT) is a microbiome-based intervention used as a placebo comparator in clinical research, specifically in the COMEBACK trial (NCT03691987) for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Developed by the University Hospital of North Norway, it involves the collection of a participant's own feces, which is then preprocessed, frozen, and thawed before being administered via enema. The goal of using an autologous preparation as a placebo is to control for the administration procedure and the presence of fecal matter while ensuring that no foreign microbiota are introduced, thereby isolating the effects of donor-derived microbiota in the active treatment arm.
- Other names
- autologous fecal microbiota transplantautologous FMT
02
Targets
FXR (Farnesoid x-activated receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on preprocessed thawed autologous FMT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on preprocessed thawed autologous FMT.